V ascular endothelial cells may play an active role in mediating immune processes that contribute to acute and chronic rejection of vascularized allografts (1, 2) . In fact, our laboratory has recently demonstrated that direct activation of CD8 ϩ T lymphocytes by allograft nonhemopoietic cells such as vascular endothelium alone can lead to allograft rejection. Furthermore, we have shown that the presence of donor-derived hemopoietic APC does not influence the tempo of CD8 ϩ direct allorecognition-mediated acute rejection (3) . Despite numerous in vitro studies evaluating the interaction between human T lymphocytes and vascular endothelium, little mechanistic data regarding the costimulatory requirements are available in a murine system (4 -6) . Although human and murine endothelial cells have different characteristics, a better understanding of interactions between endothelial cells and T lymphocytes in the mouse is necessary for a proper interpretation of biological processes in this commonly used transplantation model.
To date, there have been few studies examining the Ag-presenting capacity of mouse vascular endothelium in vitro (7) (8) (9) . This can be explained by the relative difficulty in isolating and culturing vascular endothelium from these animals (10) . In addition, the validity of a mouse model has been challenged due to interspecies differences in the phenotypes of vascular endothelium both at a resting state and after treatment with proinflammatory cytokines. The presence of MHC class II molecules on the surface of HUVEC was thought to be unique to humans, and has been used as a particular argument to question the relevance of studies in small animal models (11) . Moreover, the few studies that have examined interactions between mouse vascular endothelium and T lymphocytes have yielded conflicting results. It has been previously reported that mouse vascular endothelium is capable of direct activation of CD8 ϩ T lymphocytes with greater ease than CD4 ϩ T lymphocytes (7) . However, another study found that IFN-␥-activated endothelium failed to induce activation and proliferation of CD8 ϩ T cells in a model of indirect presentation (9) . Aside from using different modes of Ag presentation, the conflicting results of these studies might be explained by differing sources of vascular endothelium used in these experiments. For example, endothelium from the lung, which is in constant contact with environmental Ags, may not necessarily model vascular endothelium of organ allografts such as heart and kidney (12, 13) .
The purpose of this study was to characterize the mechanism underlying direct activation of CD8 ϩ T lymphocytes by mouse vascular endothelium. We have recently described a method to culture mouse vascular endothelium from the thoracic aorta (14) . This endothelium shares numerous characteristics with human endothelium, including up-regulation of MHC class I molecules and induction of MHC class II molecules under proinflammatory conditions. Interestingly, cultured mouse vascular endothelium expresses CD80, but lacks both CD40 and CD86. Because CD80 is known to be critical to activation of T cells by engaging CD28, we hypothesized that vascular endothelium activates alloreactive CD8 ϩ T lymphocytes in a B7-dependent fashion. The results of this study demonstrate that CTLA4-Ig inhibits proliferation of CD8 ϩ T cells in response to both resting and activated vascular endothelial cells. These observations have been extended to an in vivo model in which we demonstrate that proliferation of CD8 ϩ T lymphocytes in response to direct presentation by allogeneic nonhemopoietic cells, such as vascular endothelium, can be similarly inhibited by CTLA4-Ig. These findings could have important implications for the design of immunosuppressive strategies for preventing acute and chronic allograft rejection.
Materials and Methods
Mice Male C57BL/6 (H-2K b ) (designated as B6) and ␤ 2 -microglobulin-deficient mice on a C57BL/6 background (designated as B6 IϪ ) were purchased from Taconic (Germantown, NY), and male CBA/J (H-2K k ) (designated as CBA) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). They were housed under pathogen-free conditions and used at 4 -7 wk of age.
Vascular endothelium cell culture
Small pieces of thoracic aorta were isolated from B6 or CBA mice and plated endothelial side down onto 24-well plates coated with a three-dimensional type I rat tail collagen gel (14) . After a 48-h period, the cultures were supplemented with RPMI medium containing 20% heat-inactivated FCS, 2-ME (1 l/ml), gentamicin (1 l/5 ml) (Life Technologies, Gaithersburg, MD), and endothelial cell growth supplement (50 g/ml) (BD Biosciences, Bedford, MA). Endothelial cells were initially passaged onto tissue culture-treated plastic flasks using 0.3% collagenase H solution (Sigma-Aldrich, St. Louis, MO). Further passaging was conducted with 5 mM EDTA (Life Technologies). No trypsin was used during passaging to preserve surface protein expression. For functional assays, early passage endothelial cells were used either at a resting state or after activation with 500 U/ml murine rIFN-␥ (R&D Systems, Minneapolis, MN) for a period of 72 h.
Purification of CD8 ϩ T lymphocytes and cell labeling
Responder cells for coculture assays consisted of CD8 ϩ T lymphocytes isolated from unprimed CBA mice sacrificed by cervical dislocation. Spleens and pooled lymph node cells were isolated, and adherent cells were depleted from splenocytes by passage through nylon wool columns (Polysciences, Warrington, PA). Cells were then incubated with magnetic beadcoated anti-CD8 mAbs and positively selected by passage though a magnetic column (midiMACS system; Miltenyi Biotec, San Diego, CA). Purity of CD8 ϩ T lymphocytes was greater than 96%, as determined by flow cytometry. CD8 ϩ T lymphocytes were labeled with the fluorescent dye CFSE (Molecular Probes, Eugene, OR) before their coculture with endothelial cells by incubation with CFSE in PBS at a final concentration of 2 M for 3 min. To evaluate the response of naive CD8 ϩ T lymphocytes, cells were sorted based on their surface expression of CD44. Briefly, CBA cells were labeled with CD44 conjugated to PE and CD8 conjugated to allophycocyanin, and sorted on FACSVantage sorter (BD Biosciences), with a purity exceeding 99%. CD44 low CD8 ϩ T lymphocytes were then labeled with the fluorescent dye CFSE before their coculture with endothelial cells.
In vitro proliferation assays
Endothelial cells (2.5 ϫ 10 4 /well) were plated in 48-well plates. At this initial seeding density, they reached confluence 5 days after plating. For certain conditions, endothelial cells were activated by treatment with murine rIFN-␥ (500 U/ml) 72 h before their use as stimulators and were irradiated with 25 Gy from a 137 Cs source immediately before the addition of T lymphocytes. After several washes to remove all traces of IFN-␥ from the endothelium, 5 ϫ 10 5 CD8 ϩ T lymphocytes, resuspended in 1 ml of RPMI medium containing 2-ME (1 l/ml), gentamicin (50 pg/5 ml), and 10% FCS, were added to each well. Some cultures received CTLA4-Ig (15 g/ml) (Bristol-Myers Squibb Pharmaceuticals, Princeton, NJ) or control hamster Ig (15 g/ml) (The Jackson Laboratory). CFSE-labeled CBA CD8 ϩ T lymphocytes were also cocultured with B6 splenocytes at a stimulator:responder ratio of 1:3 in 96-well round-bottom plates. B6 splenocytes were irradiated in a manner identical with the vascular endothelial cells. Proliferative responses were analyzed after 3, 5, and 7 days of coculture. CD8-specific Abs identified CBA CD8 ϩ T lymphocytes. When splenocytes were used as stimulators, Abs specific for H-2K k were also used.
Flow cytometry
All Abs and reagents for flow cytometric analysis of surface markers on endothelial cells and T lymphocytes were conjugated with PE or allophycocyanin and were purchased from BD PharMingen (San Diego, CA). Abs used for surface staining included anti-H-2K b (clone AF6-88.5), anti-H-2K k (clone 36-7-5), anti-CD40 (clone 3/23), anti-CD54 (ICAM-1) (clone 3E2), anti-CD80 (B7.1) (clone 16-10A1), anti-CD86 (B7.2) (clone GL1), anti-CD8a (clone 53-6.7), anti-CD25 (clone PC61), anti-CD69 (clone H1.2F3), anti-CD44 (clone IM7), and anti-CD95 ligand (Fas ligand) (clone MFL3). To determine the level of contamination with hemopoietic elements, the cultures were stained with the leukocyte common marker CD45 (leukocyte common Ag) (clone 30-F11). Appropriately labeled isotype control Abs of rat, hamster, and mouse origin were used. All samples were acquired on a FACSCalibur (BD Biosciences) and analyzed using the CellQuest software package (BD Biosciences).
Intracellular staining for Bcl-x L and cytokines
Expression of the antiapoptotic protein Bcl-x L and the ability to produce cytokines were assessed at the single cell level. PE-conjugated anti-Bcl-x L Ab (clone 7B2.5) and the appropriate isotype control were purchased from Southern Biotechnology Associates (Birmingham, AL). PE-conjugated Abs against IL-2 (clone JES6-5H4), IL-4 (clone 11B11), IFN-␥ (clone XMG1.2), and the appropriate isotype control were purchased from BD PharMingen. After the indicated time points of coculture of CD8 ϩ T lymphocytes with endothelial cells, T cells were surface stained for 30 min in a small volume of cold PBS, followed by a 60-min period of fixation in 2.5% paraformaldehyde (Sigma-Aldrich) on ice. Cells were then permeabilized with 0.1% saponin (Sigma-Aldrich) in PBS containing 2% FCS for 10 min on ice. Intracellular staining was performed for 30 min, with the cells resuspended in a small volume of 0.1% saponin. After two washes in 0.01% saponin, the cells were resuspended in PBS containing 2% FCS and analyzed by flow cytometry. The staining protocol for intracellular cytokines was similar. However, before surface staining, cells were cultured with 20 ng/ml PMA (Sigma-Aldrich) and 1 M ionomycin (Calbiochem, La Jolla, CA) for 4 h, and 2 M monensin (Sigma-Aldrich) was added for the last 3 h of culture.
Intracellular perforin staining
To detect intracellular perforin, cells isolated from individual wells of endothelial cell/T lymphocyte cocultures were fixed with 2% paraformaldehyde for 20 min on ice. The cells were then washed and permeabilized with 0.1% saponin containing 2% FCS for 10 min on ice. Cells were subsequently incubated with goat serum for 10 min and then stained with antiperforin Ab (clone P1-8) (Kamiya Biomedical, San Diego, CA) in 0.3% saponin for 30 min on ice. Following one wash in 0.1% saponin, cells were incubated with PE-labeled polyclonal goat anti-rat Ab (Southern Biotechnology Associates) in 0.3% saponin for 30 min on ice. After two washes in 0.01% saponin, cells were resuspended in PBS containing 2% FCS and stained with APC-labeled anti-CD8a Ab for 30 min on ice. Subsequently, the cells were washed twice in cold PBS containing 2% FCS.
Creating chimeric organs by bone marrow transplantation
Bone marrow chimeras were created as previously described (15) . Briefly, for bone marrow transplantation, male wild-type B6 were reconstituted with marrow from B6 IϪ mice. Bone marrow was harvested from the femora of donor mice, and T lymphocytes were depleted with anti-CD90 (Thy)-labeled magnetic microbeads (Miltenyi Biotec). Recipient mice received an inoculum of 1 ϫ 10 7 T cell-depleted donor bone marrow via lateral tail vein injection 6 h after lethal irradiation. These bone marrow chimeras were used for in vivo MLRs at least 90 days after the bone marrow transplant. These bone marrow chimeras lacked expression of H-2K
b on their hemopoietic APC such as dendritic cells and macrophages (15) . The following designation is used to describe chimeric organs: nonhemopoietic cells (hemopoietic APC).
In vivo proliferation assays
Responses of CBA CD8 ϩ T lymphocytes to direct allopresentation by nonhemopoietic cells were tested in vivo. Wild-type B6 or B6(B6 IϪ ) mice were treated with supralethal irradiation (18 Gy) from a cesium source and then received an adoptive transfer of 25 ϫ 10 6 CFSE-labeled CD8 ϩ CBA T lymphocytes via tail vein injection within 4 h of irradiation. For certain experiments, B6(B6 IϪ ) bone marrow chimeras were treated with 100,000 U IFN-␥ via i.p. injection 72 h before irradiation. Certain mice received CTLA4-Ig (200 g) (Bristol-Myers Squibb Pharmaceuticals) or control hamster Ig (200 g) (The Jackson Laboratory) at the time of the adoptive transfer of the CFSE-labeled CD8 ϩ T lymphocytes. Animals were sacrificed 72 h later. To assess the proliferative responses of the adoptively transferred CBA CD8
ϩ T cells, their spleens and peripheral lymph nodes were analyzed by flow cytometry. These cells were identified by staining with Abs specific for H-2K k as well as CD8.
RT-PCR analysis of aortic tissue
Spleens were removed from wild-type B6 mice, and thoracic aortas were removed from wild-type B6 mice and IFN-␥-treated wild-type B6 mice. RNA was then isolated from these tissues. A total of 2 g RNA was reverse transcribed at 55°C for 45 min for MHC class I and 58°C for 60 min for CD45 and amplified with EZ RTth Taq kit (PerkinElmer/Cetus, Norwalk, CT) and with 300 g primers: MHC I sense (5Ј-ACATG GAGCTTGTGGAGACC-3Ј), MHC I antisense (5Ј-CAAGGACAACCA GAACAGCA-3Ј), CD45 sense (5Ј-GCACCAGCTGATCTCCAGATA-3Ј), CD45 antisense (5Ј-CAAACACCTACACCCAGT-3Ј), ␤-actin sense (5Ј-ATCACCATTGGCAATGAGCGGTTCC-3Ј), and ␤-actin antisense (5Ј-CTCGTCATACTCCTGCTTGCTGAT-3Ј). Thermocycling was performed on a Hybaid 900 (Hybaid, Middlesex, U.K.) using the following parameters: for MHC class I, 94.5°C for 120 s, followed by 36 cycles of 94.5°C for 30 s and 55°C for 150 s. For CD45, 95°C for 120 s, followed by 36 cycles of 95°C for 30 s and 58°C for 90 s.
Results

Vascular endothelium: phenotypic changes after activation
Mouse vascular endothelium isolated from thoracic aorta expresses low levels of MHC class I (H-2K b ) and moderate levels of CD80 (B7-1) on its surface at a resting state. Although it also expresses CD54 (ICAM-1), there is no detectable CD40 or CD86 (B7-2). MHC class I levels are markedly up-regulated after a 72-h period of treatment with IFN-␥ (500 U/ml), while expression levels of CD80 do not change (14) . We have also observed a mild increase in CD54 expression, while treatment with IFN-␥ did not induce expression of CD40 or CD86. Lack of contamination with hemopoietic cells was documented by flow cytometry as well as RT-PCR, which demonstrated no expression of CD45 (3).
Proliferation of CD8 ϩ T cells after coculture with vascular endothelium
The phenotype of mouse vascular endothelium indicates that it has the means to activate unprimed alloreactive CD8 ϩ T lymphocytes both at a resting state and after activation. Treatment with IFN-␥ enhances signal 1 (MHC class I) to a greater extent than signal 2 (CD80). We have recently demonstrated the ability of resting B6 vascular endothelium to induce proliferation of CD8 ϩ T cells isolated from a TCR transgenic mouse, in which the transgene reacts with the allogeneic MHC class I H-2K b (3) . To test whether resting or activated endothelial cells can induce proliferation of wild-type CD8 ϩ T cells, we labeled the responder CD8 ϩ T cell population with the fluorescent dye CFSE before initiation of coculture. Due to equal segregation of this dye between daughter cells upon cell division, halving of cellular fluorescence indicates one round of proliferation (16, 17) . Similar to splenocytes, both resting and activated vascular endothelium induce proliferation of allogeneic CD8 ϩ T lymphocytes (Fig. 1A) . Interestingly, the CFSE division profiles indicate differences in the kinetics of clonal expansion between the stimulator conditions. Alloreactive CD8 ϩ T lymphocytes start proliferating after longer time periods of coculture with resting endothelium when compared with both activated endothelium and splenocytes. However, while CD8 ϩ T lymphocytes start proliferating after shorter time periods in response to activated vascular endothelium and a higher proportion of CD8 ϩ T lymphocytes are recruited into the proliferating pool at earlier time points, both resting and activated vascular endothelium recruit a similar proportion of CD8 ϩ T lymphocytes into the proliferating pool after 7 days of coculture. No significant proliferation was observed when CBA CD8 ϩ T lymphocytes were cocultured with syngeneic endothelium (Fig. 1B) . T cells that have undergone at least one round of cell division after coculture with resting or activated endothelium show the hallmarks of activation, such as CD69 and CD25 expression (Fig. 1C) . Importantly, CFSE-labeled CBA CD8 ϩ T cells cultured alone in vitro do not show any evidence of activation, such as surface expression of CD25 or CD69. Of note, activated vascular endothelium was also able to induce proliferation of naive CD44 low CD8 ϩ T lymphocytes, while only minimal proliferation of this cell population was observed after 7 days of coculture with resting endothelium (Fig. 1D) . Taken together, our results indicate that vascular endothelium has the capacity to activate and induce proliferation of alloreactive wild-type CD8 ϩ T lymphocytes in vitro.
Cytokine profile and effector phenotype
Similar to CD4
ϩ T cells, CD8 ϩ T cells have the capacity to express several cytokine programs and differentiate into either T c 1 or T c 2 cells (18, 19) . The type of APC has been discussed as a contributory factor in determining this differentiation of the responding T cells (20) . In addition to cytokine secretion by APC, their relative expression of MHC molecules and costimulatory molecules have been discussed as contributing factors (21, 22) . Consequently, we were interested in examining the ability of CD8 ϩ T cells, activated through vascular endothelium by direct allorecognition, to produce cytokines. Cells were stimulated in vitro with PMA and ionomycin for 4 h before cytokine staining. This assay determines whether CD8 ϩ T cells that have been activated by coculture with vascular endothelium have been primed to produce cytokines. A large percentage of cells that had undergone division were able to produce IFN-␥ after coculture with both resting and activated vascular endothelium ( Fig. 2A) . Additionally, we were able to detect the ability to produce IL-2 among cells that had divided (Fig. 2B) . However, this percentage was smaller than those producing IFN-␥, which is consistent with previous studies (23) . We were unable to detect production of cytokines known to be associated with T c 2 differentiation, such as IL-4 (Fig. 2C) . CD8 ϩ T lymphocytes that produce cytokines associated with a T c 1 phenotype are known to have the potential to further differentiate into effector cells. To this end, we determined their expression of perforin and Fas ligand, both of which are known to contribute to the cytotoxic ability of CD8 ϩ T lymphocytes (24, 25) . We found that the majority of CD8 ϩ T lymphocytes that had undergone cell division after coculture with resting or activated vascular endothelium expressed perforin (Fig. 3A) . Similarly, Fas ligand was up-regulated on CD8 ϩ T cells that had progressed through the cell cycle (Fig. 3B) . Thus, we have established that CD8 ϩ T cells acquire a cytotoxic armamentarium after activation through vascular endothelium.
Costimulatory blockade
Given the presence of CD80 on cultured vascular endothelium, we postulated that its expression is important in the ability of endothelial cells to activate CD8 ϩ direct allorecognition. We found that when CD28 costimulation is blocked in the presence of CTLA4-Ig, the proliferative response of alloreactive CD8 ϩ T lymphocytes to resting and activated vascular endothelium is markedly blunted (Fig. 4A) . The minimal proliferative response after 7 days of coculture in the presence of CTLA4-Ig is comparable with that after coculture with syngeneic endothelium, indicating that direct activation of alloreactive CD8 ϩ by vascular endothelium is B7 dependent. Consistent with the lack of CD40 expression on resting as well as activated cultured vascular endothelium, addition of the CD40-blocking agent MR-1 did not inhibit proliferative responses of CD8
ϩ T lymphocytes to allogeneic endothelial cells. Moreover, disrupting costimulation through ICAM-1 did not lead to diminished proliferative responses (data not shown).
Expression of antiapoptotic protein Bcl-x L
Expression of the antiapoptotic protein Bcl-x L in activated T lymphocytes alters their apoptotic threshold and protects them from apoptotic stimuli, such as that of growth factor withdrawal or treatment with glucocorticoids (26) . Up-regulation of Bcl-x L has been described in T cells following activation through B7-dependent mechanisms (27) . Having shown that the interaction between CD80 on the surface of vascular endothelium and CD28 on the T cells is critical for the division and activation of alloreactive T cells, we set out to examine whether vascular endothelium has the capacity to up-regulate Bcl-x L in CD8 ϩ T lymphocytes. We found that the vast majority of T cells that have progressed through the cell cycle at least once expressed high levels of Bcl-x L after coculture with both resting and activated endothelium. Treatment of the cultures with CTLA4-Ig reduced the absolute number of T lymphocytes that entered the cell cycle and consequently reduced the number of T lymphocytes expressing Bcl-x L . Of note, the few T cells that divide in cultures treated with CTLA4-Ig express Bclx L , raising the possibility that costimulation through CD28 may not be the sole mechanism inducing the expression of this antiapoptotic protein (28, 29) . Nevertheless, the observation that cell division and the number of T lymphocytes expressing Bcl-x L are both reduced by CTLA4-Ig indicates that mouse vascular endothelium has the capacity not only to induce proliferation and differentiation, but also potentially regulate survival in a B7-dependent fashion (Fig. 4B) .
Proliferation of CD8 ϩ T cells after in vivo activation by nonhemopoietic cells
To assess whether nonhemopoietic cells such as vascular endothelium had the ability to induce proliferation of alloreactive CD8 ϩ T lymphocytes in vivo, we used an assay in which CFSE-labeled CBA CD8
ϩ T lymphocytes are adoptively transferred into whole body irradiated B6 mice. Vigorous proliferation was seen when CBA CD8 ϩ T lymphocytes were adoptively transferred into wildtype B6 hosts (Fig. 5A) . In this experimental group, both hemopoietic and nonhemopoietic cells of B6 origin can contribute to the activation of the CBA CD8 ϩ T lymphocytes. To determine whether nonhemopoietic B6 cells can induce proliferation of alloreactive CD8 ϩ T lymphocytes in vivo, we created B6 bone marrow chimeras in which the hemopoietic APC are derived from ␤ 2 -microglobulin-deficient mice and therefore lack surface expression of MHC class I (B6 IϪ ). Our laboratory has previously shown that the level of hemopoietic APC replacement in all tissues of these bone marrow chimeras amounts to over 99.99%, as determined by semiquantitative RT-PCR, with no contribution to allorecognition as assessed by MLR (15 (Fig. 5B) . Because this assay is limited by the death of the majority of irradiated hosts by ϳ96 h after irradiation and we have observed differences in kinetics between stimulation by resting and cytokine-activated vascular endothelium in vitro, we treated B6(B6 IϪ ) bone marrow chimeras with systemic IFN-␥ 72 h before adoptive transfer of CBA CD8 ϩ T lymphocytes. Consistent with previous reports, this regimen leads to up-regulated expression of MHC class I on vascular endothelial cells, as confirmed by RT-PCR (30) (Fig. 6A) . Furthermore, these cells were negative for CD45 by RT-PCR analysis, indicating that the upregulated MHC class I expression was due to increased transcription in vascular endothelium and not to the presence of professional APCs (Fig. 6B) . Approximately one-third of CBA CD8
ϩ T lymphocytes present 84 h after adoptive transfer had undergone at least one round of cell division, indicating that nonhemopoietic cells are able to induce the proliferation of alloreactive CD8 ϩ T lymphocytes (Fig. 5C ). Having shown that the proliferative response of CD8 ϩ T lymphocytes to vascular endothelium is dependent on B7 in vitro, we next questioned whether the proliferative response to cytokine-activated nonhemopoietic cells in vivo could also be inhibited by CTLA4-Ig. Systemic administration of CTLA4-Ig inhibited the proliferation of CBA CD8 ϩ T lymphocytes, which had been adoptively transferred into IFN-␥-treated B6(B6 IϪ ) bone marrow chimeras. This suggests that nonhemopoietic cells can activate alloreactive CD8 ϩ T lymphocytes in a B7-dependent fashion in vivo (Fig. 5D ).
Discussion
Although hemopoietic professional APC of donor origin are critical stimuli for direct allopresentation in the early postengraftment period, their number decreases substantially over time (31) . Vascular endothelium, however, remains present at the graft-host interface for the duration of the graft and could, therefore, provide a lasting stimulus for direct allorecognition. We have recently demonstrated that nonhemopoietic cells, such as vascular endothelium, can serve as potent stimulators for CD8 ϩ direct allorecognition (3). A better understanding of endothelial-driven direct Ag presentation could lead to novel therapeutic strategies for the prevention and treatment of both acute and chronic rejection. Furthermore, studies analyzing the underlying mechanism of activation of lymphocyte subsets by mouse vascular endothelium may prove significant in correctly interpreting observations made in commonly used murine transplantation models that examine allorecognition pathways.
Similar to observations previously made for endothelial cells derived from human umbilical veins, our results show that both resting and activated vascular endothelial cells are capable of activating and inducing proliferation of alloreactive CD8
ϩ T lymphocytes (4). Moreover, CD8 ϩ T lymphocytes start proliferating sooner, and the response appears more vigorous at earlier time points when they are cocultured with activated endothelium within our system. This observation is in apparent contradiction to a recent study that reported lack of CD8 ϩ lymphocyte proliferation stimulated by activated microvascular endothelial cells isolated from murine lung tissue (9) . Similar to the phenotype of the endothelial cells used in the present study, the authors report that MHC class I molecules are up-regulated after treatment with IFN-␥, while CD80 expression is unchanged after activation. Marelli-Berg et al. (9) attribute the reduced immunogenicity of activated endothelium to a failure to up-regulate CD80 after treatment with IFN-␥, which leads to an imbalance between TCR engagement and CD28 engagement after activation. In contrast, our results suggest that higher levels of signal 1 in activated endothelium probably lead to an enhancement in TCR occupancy, with more T cells being recruited into the proliferating pool at earlier time points. However, it should be pointed out that the apparent discrepancies between these studies could be attributed to the different sources of endothelium used. Microvascular endothelium isolated from the pulmonary system is constantly exposed to environmental Ags. Because tolerance for inhaled Ags may be due to altered function of APC at these sites, conclusions drawn from endothelium isolated from lung tissue may not reflect the immunologic function of macrovascular endothelium from an internal, protected source, as described in this work. As we have recently shown that nonhemopoietic cells such as vascular endothelium can trigger acute rejection of cardiac allografts via CD8 ϩ direct allorecognition, it would be interesting to explore whether vascular endothelial cells can trigger rejection of vascularized allografts exposed to environmental Ags, such as lungs (3) . Another important difference between our experimental system and Lechler's study (9) is that we have focused on CD8 ϩ direct allorecognition, important to the field of solid organ transplantation, while the other group has focused on self MHC-restricted recognition of a nominal Ag. The ability of vascular endothelium to induce proliferation of naive CD8
ϩ T lymphocytes has also been the subject of controversy. Although it was initially reported in a human system that resting endothelium is incapable of inducing proliferation of naive CD8 ϩ T cells, a subsequent finding in a murine model suggests otherwise (4, 9) . Similarly, we have recently reported that resting endothelium is capable of activating CD44 low CD8 ϩ T cells in a TCR transgenic system (3). In this study, while we did not observe proliferation of CD44 low CD8 ϩ wild-type CBA T cells after coculture with resting endothelium, activated endothelium did induce proliferation of CD44 low CD8 ϩ T cells. Taken together, these observations may be a reflection of different experimental systems.
Similar to human vascular endothelium, expression of MHC class I molecules is strongly up-regulated on our mouse endothelial cells after treatment with proinflammatory cytokines (32) . An important distinction between HUVEC and our endothelial cells is the inability to induce expression with CD40 after treatment with IFN-␥ (33). Furthermore, it is well documented that interspecies differences exist with regard to the endothelial expression of B7. Cultured human endothelial cells do not express B7, and endothelium-driven activation of alloreactive T lymphocytes is contingent upon the costimulatory molecules LFA-3 and CD2 (34, 35) . However, it is important to note that CD86 and CD80 are expressed on porcine and mouse vascular endothelium, respectively (14, 35) . Despite these differences in surface expression of costimulatory molecules, our findings in the mouse system extend observations made in large animal and human models that vascular endothelium has the ability to directly activate alloreactive T cells.
Several studies in murine models have documented the ability to suppress alloimmune responses with blockade of costimulatory signals, particularly the B7-CD28 and CD40-CD40 ligand interactions (36, 37) . Marked suppression of the proliferative response of CD8
ϩ T cells to cultured vascular endothelium in vitro and to nonhemopoietic cells in vivo after treatment with CTLA4-Ig demonstrates that this direct activation of CD8 ϩ T lymphocytes occurs in a B7-dependent fashion. In addition to its effect on IL-2 transcription, B7 molecules have been shown to up-regulate the expression of the antiapoptotic protein Bcl-x L (27) . Increasing the number of T lymphocytes expressing Bcl-x L as a consequence of interaction with endothelial cells raises the interesting possibility that the survival of alloreactive T lymphocytes may be regulated at the level of the allograft. Our results suggest that the administration of CTLA4-Ig in a mouse allotransplantation model could have the additional benefit of blocking the survival signal that alloreactive T lymphocytes receive at the level of the allograft. Differentiation of in vitro stimulated CD8 ϩ T lymphocytes into effector cells involves the development of intracellular stores of proteins required for the granule exocytosis cytotoxic pathway as well as TCR-induced transcription and surface expression of Fas ligand (38, 39) . We have demonstrated that proliferating CD8 ϩ acquire intracellular perforin and express Fas ligand after coculture with mouse vascular endothelium. These findings parallel observations in human in vitro studies using HUVEC as stimulators (40) . Interestingly, human CD8 ϩ T cells that have been cocultured with endothelial cells acquire endothelial cell-specific cytotoxic activity, while failing to lyse B lymphoblastoid targets from the same donor (6) . The authors speculate that this could be due to cell-specific interactions that occur during the differentiation of CD8 ϩ T cells into effector cells. The question, whether mouse CD8 ϩ T cells, which acquire cytotoxic characteristics after coculture with vascular endothelial cells, display target cell selectivity like their human counterparts, will be explored in future studies. Examining this issue will be particularly interesting in light of the differences in costimulatory interactions between mice and humans that account for the activation of alloreactive CD8 ϩ T lymphocytes. The lack of B7 expression on human endothelial cells in particular may have important consequences for their differentiation into effector cells. A recent study found that either B7 or IL-2 is sufficient for the generation of CD8 ϩ CTL in a mouse system (41) . Unlike the case for the human studies, in which exogenous IL-2 is added to the cultures during CTL differentiation, no cytokines are supplemented within our murine cultures (6, 40, 42) .
Many immunosuppressive strategies in murine allotransplantation models have focused on perioperative depletion of CD4 ϩ T lymphocytes in the host or perioperative administration of agents that block costimulation (37, 43) . The main goal of these approaches is to reduce the strength of CD4 ϩ direct allorecognition triggered by donor-derived hemopoietic APC. Despite reports of prolongation of allograft survival, the success of these protocols often depends on the strain combination used, and many allografts that survive long-term show evidence of chronic rejection (37, 44) . In this study, we have shown that direct activation of CD8 ϩ T lymphocytes by mouse vascular endothelial cells is B7 dependent. Because allogeneic nonhemopoietic cells such as vascular endothelium remain in the graft indefinitely, long-term administration of costimulatory blockade, including CTLA4-Ig, might be necessary to blunt direct allorecognition and induce immunological tolerance.
